Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI (CanTi)

June 27, 2018 updated by: Jacob Sørensen, University of Aarhus

Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction

This randomized, controlled trial compares the anti-thrombotic effect of cangrelor and ticagrelor on platelet activity in patients with acute ST-elevation myocardial infarction.

Patients will receive either prehospital ticagrelor (180 mg - crushed) or in-hospital cangrelor (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) followed by 180 mg ticagrelor.

The primary study end-point is platelet reactivity at sheath insertion, at the end of the PCI procedure (before sheath removal) and two hours after PCI is initiated. The secondary end-point is the proportion of patients with inappropriate or harmful P2Y12 administration.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

In patients with ST-elevation myocardial infarction (STEMI) early restoration of blood flow in the culprit coronary artery is essential to reduce infarct size and thereby mortality and morbidity. The recommended method for achieving reperfusion is primary percutaneous coronary intervention (PPCI) (1,2). Early initiation of adjunctive antithrombotic therapy is important to prevent further thrombus formation and to facilitate PPCI.

International guidelines currently recommend immediate oral or intravenous administration of aspirin and intravenous administration of heparin in patients with suspected STEMI (1,2).

A second platelet inhibitor (of the P2Y12 family) is often added already in the ambulance. This enhances the antiplatelet effect, but also increases bleeding risk.

A recently introduced antithrombotic agent, that can be administered intravenously, can potentially achieve the same antithrombotic effect at the same time of the oral agent, with the added benefit, that administration can await coronary angiography. This would reduce the risk of administrating powerful antithrombotic medicine to patients with diagnosis other than STEMI.

In the ATLANTIC trial (3) prehospital administration was compared to in-hospital (catheterization laboratory) administration of ticagrelor. The trial indicated that ticagrelor could safely be administered in the ambulance, although there was no apparent effect on Thrombolysis in Myocardial Infarction (TIMI) flow in the culprit coronary artery and no effect on ST-segment resolution in the ECG. However, the median time difference between ticagrelor administration in the two groups was only 31 minutes. This might not leave enough time for adequate platelet inhibition in the prehospital group.

In patients with NSTEMI (Non-ST-elevation myocardial infarction), pretreatment with prasugrel has been shown to be associated with increased bleeding risk and confers no benefit on ischemic outcomes (4). Thus, there are indications that the addition of oral P2Y12 inhibitor can await the coronary angiography, thereby minimizing the risk of excessive platelet inhibition in patients with a high bleeding risk or a potentially lethal differential diagnosis such as aortic dissection (5). Previous studies document that approximately 15% of patients with suspected STEMI have a final diagnosis other than an acute coronary syndrome (6). There is a fine balance between the benefit and possible deleterious effects of early, aggressive oral platelet inhibition in patients with suspected STEMI.

Recently a novel, intravenous P2Y12 inhibitor - cangrelor - has been released. Cangrelor enables immediate inhibition of the platelet P2Y12 inhibitor. The drug has a short half-life, is reversible and is only effective during administration (7). This contrasts with the available oral P2Y12 inhibitors, which all induce inhibition of the platelets for several days. Although ticagrelor is reversible, the platelet inhibition induced by this widely used, potent drug lasts for at least 3 days (8). The effects of cangrelor on platelet inhibition and clinical outcome have been documented in three, large clinical randomized trials (9-11).

Currently it is unknown whether platelet inhibition achieved by cangrelor administered in the catheterization laboratory is more effective compared to ticagrelor administered in the ambulance in patients with suspected STEMI.

The objective of this trial is to compare the effect of oral ticagrelor vs. intravenous cangrelor on platelet inhibition in ST-elevation myocardial infarction.

Patients will be included in the ambulance and randomized to one of two treatment groups; either to receive oral ticagrelor or intravenous cangrelor.

The study randomization will not be blinded to either investigator or patient (Open label, randomized, controlled clinical trial).

The hypothesis is that platelet inhibition with cangrelor administered intravenously in the catheterization laboratory after coronary angiography, but before PPCI is as effective as platelet inhibition achieved by ticagrelor administered orally in the ambulance in patients with suspected STEMI.

It is also assumed that administration of a P2Y12 inhibitor after coronary angiography reduces the proportion of inappropriate administration due to a final diagnosis other than STEMI.

Study Type

Interventional

Enrollment (Anticipated)

80

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Jacob T Sorensen, MD, PhD
  • Phone Number: +4540143563
  • Email: jacsoe@rm.dk

Study Contact Backup

Study Locations

  • Denmark
      • Aarhus, Denmark, 8200
        • Aarhus University Hospital
        • Contact:
          • Jacob Thorsted Sorensen, MD, PhD
          • Phone Number: +4540143563
          • Email: jacsoe@rm.dk
        • Contact:
          • Steen D Kristensen, MD, DMSc
          • Phone Number: +4530922336
          • Email: stekrist@rm.dk

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients triaged for PPCI due to suspicion of STEMI.
  2. Symptom duration < 12 hours

Exclusion Criteria:

  1. Previous inclusion in the study
  2. Already in treatment with ticagrelor, prasugrel or clopidogrel
  3. Treatment with oral anticoagulants (warfarin, coumarins, rivaroxaban, apixaban, dabigatran)
  4. Adjunctive use of glycoprotein IIb/IIIa inhibitor during PCI
  5. Active bleeding
  6. Known, severe kidney failure (GFR < 30 ml/min) and/or liver disease
  7. Women of child bearing ability who are not using contraceptive medication
  8. Severe mental or psychiatric disease, altered mental state (including unconsciousness) making it impossible to achieve informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Prehospital ticagrelor

Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.

In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication.
Drug: Ticagrelor
ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
Other Names:
  • Brilinta
  • Brilique
Active Comparator: Inhospital cangrelor tetrasodium

Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.

In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication.
Drug: Ticagrelor
ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
Other Names:
  • Brilinta
  • Brilique
Drug: Cangrelor Tetrasodium
Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
Other Names:
  • Kengreal
  • Kengrexal

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelet reactivity 10 minutes PCI after is initiated
Time Frame: 10 minutes
Platelet reactivity measured in platelet reactivity units (PRU) by the VerifyNow® assay 10 minutes after PCI is initiated.
10 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelet reactivity before and after PCI
Time Frame: 2 hours
Effect on platelet reactivity, measured by VerifyNow® after sheath insertion, at the end of the PCI procedure (before sheath removal) and two hours after PCI is initiated
2 hours
Proportion of patients with inappropriate or harmful P2Y12 administration
Time Frame: 4 hours
This is defined as patients with a diagnosis other than acute myocardial infarction or patients where prehospital ticagrelor administration delays surgery (cardiac or other) due to excess bleeding risk.
4 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Aarhus

Investigators

  • Principal Investigator: Jacob T Sorensen, MD, PhD, Aarhus University Hospital, Department of Cardiology, Skejby
  • Study Director: Steen D Kristensen, MD, DMSc, Aarhus University Hospital, Department of Cardiology, Skejby

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 1, 2018

Primary Completion (Anticipated)

June 1, 2019

Study Completion (Anticipated)

August 1, 2019

Study Registration Dates

First Submitted

June 7, 2017

First Submitted That Met QC Criteria

June 7, 2017

First Posted (Actual)

June 9, 2017

Study Record Updates

Last Update Posted (Actual)

June 28, 2018

Last Update Submitted That Met QC Criteria

June 27, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2016-003721-41

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction

Clinical Trials on Ticagrelor

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe